Amivantamab (Rybrevant) in combination with carboplatin and pemetrexed, will shortly be assessed by the Scottish Medicines Consortium (SMC) for use in NHS Scotland.
The indication that this medicine will be assessed under is, for the” first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon20 insertion mutations.”
We have been invited to provide a Patient Group Submission for the indications of this medicine, and are therefore trying to gather some patients’ experience quotes in support for this proposed treatment; you do not have to live in Scotland to comment and it would be extremely helpful to know the following:
What is your experience of living with EGFR positive EXON 20 mutation lung cancer and how does this affect your quality of life.
What has been your experience of treatment options with EGFR positive Exon 20 mutation NSCLC?
If you are happy to comment on any of the questions, please get in touch, no personal details are needed but discussing it with you will help us put together the document on behalf of patients.
Please either comment below, private message or email ann.doran@roycastle.org, alternatively, you can phone the Roy Castle Ask the Nurse service on 0800 358 7200 Monday to Thursday 0900-1700 and Friday 0900-1600
All comments are welcome, so please do get in touch.
Thank you in advance.
Ann Doran
The Roy Castle Lung Cancer Foundation
£170 for taking part in Phone Research
